Hongjing Xia
Principal Scientist Novartis AG
Hongjing Xia is a team lead with deep expertise in cutting-edge technologies in cell and gene therapy. Her work focuses on advancing next-generation delivery platforms targeting T cells and hematopoietic stem cells (HSCs), with the goal of enabling transformative therapeutics for autoimmune disorders and sickle cell disease.
Seminars
Thursday 4th June 2026
Evaluating PEG-Alternative LNPs for Extrahepatic Delivery in In Vivo Cell Reprogramming
1:00 pm
- Novel Ionizable Lipid: Demonstrates enhanced T-cell tropism with reduced hepatic uptake
- In Vivo Characterization: Ongoing studies on biodistribution, safety, and toxicity profiles
- Formulation Strategy: Assessing PEG-alternatives in combination with ionizable lipids for delivery feasibility
